10/20 Taiwan BIO Weekly
2025-10-20 |
| Taiwan BIO Weekly |
| Unicocell Biomed accelerates expansion, aiming for operational turning point by 2026 17 October, 2025 Unicocell Biomed (TW: 6794) has begun trading on the main stock trading board, becoming Taiwan’s first regenerative medicine stem cell company listed on the general market. The company stated that higher visibility in the capital markets and greater fundraising flexibility will accelerate clinical trial progress and international market expansion, aiming for a critical operational turning point by 2026. The company also announced that its core product, ELIXCYTE, for treating knee osteoarthritis, is in Phase III clinical trials, with patient enrollment expected to be completed by the end of this year and full trial completion targeted for next year. Another stem cell drug for chronic kidney disease has completed Phase I/II review and obtained US FDA Fast Track designation, with subsequent clinical development continuing. More... (in Chinese) |
| AmCad BioMed's sleep monitoring device enters Turkish market 17 October, 2025 AmCad BioMed (TW: 4188) has taken another step in its global expansion. The company announced that its non-overnight, ultrasound-based smart sleep monitoring device, AmCAD-UO, has signed an exclusive agreement with a Turkish distributor and received its first orders this month. AmCad mentioned that Turkey has a population of over 87 million and a healthcare market approaching US$30 billion. The local distributor is a well-known cardiologist with a chain of clinics and extensive marketing resources, which will help accelerate the device's adoption in the Turkish market. More... (in Chinese) |
| Taiwan hospital debuts AI dialysis platform to boost efficiency, safety 16 October, 2025 Tri-Service General Hospital (TSGH) yesterday unveiled Taiwan's first AI-powered dialysis platform, saying it would enhance the efficiency and mobility of the blood filtering process for patients with severe kidney disease. The new platform integrates information systems, AI decision support and mobile apps to not only allow a smoother delivery process, but also faster detection of dialysis complications, the Taipei hospital said. More... |
| Taiwan Precision Medicine Initiative Enables Large-Scale Studies 15 October, 2025 In the realm of global genetic research, there remains a significant imbalance in the representation of various ethnic groups. Despite Han Chinese individuals constituting nearly 20% of the world's population, they have been starkly underrepresented in genetic studies. This glaring disparity has prompted urgent calls for the establishment of large-scale cohorts tailored to this demographic, essential for advancing the field of precision medicine. Addressing this critical need, the Taiwan Precision Medicine Initiative (TPMI) emerges as a groundbreaking effort spearheaded by Academia Sinica in partnership with sixteen leading medical centers across Taiwan. More... |
| PharmaEssentia completes Ropeg pen injector application, prepares NDA submission for new ET indication 15 October, 2025 PharmaEssentia (TW: 6446) announced that it has submitted a supplemental Biologics License Application (sBLA) to the US FDA for its Ropeg pen injector, a treatment for rare blood cancers. The company also plans to file an additional application by the end of this year for a new indication, essential thrombocythemia (ET). These two major milestones are expected to expand Ropeg's presence in the hematologic oncology market and inject new momentum into the company’s operations. More... (in Chinese) |
| Asia University partners with NucleicAI to build Sovereign AI Life Science Data Platform in Taiwan 14 October, 2025 Asia University will partner with NucleicAI LLC, a next-generation platform and data company specialising in AI-driven genomics, precision medicine, and health intelligence, to build a Sovereign AI Life Science Data Platform in Taiwan. The platform will be hosted in-country, supporting secure data sharing, advanced analytics, and research collaboration while preserving data sovereignty. More... |
| Compal Health merges with Jubo Health to tap into long-term care market 14 October, 2025 Compal (TW: 2324) announced that its subsidiary, Compal Health, will merge into Jubo Health, with the agreement formally signed on October 13, and January 1, 2026 set as the merger reference date. Following the merger, Compal Health will become a 100% subsidiary of Jubo Health. Compal is expected to hold approximately 11.1% of Jubo Health on a fully diluted basis, becoming the largest corporate shareholder of the company. More... (in Chinese) |
| Taiwan positions for global biopharma growth as billion-dollar drug patents expire 13 October, 2025 Taiwan's pharmaceutical industry is positioning itself for greater global competitiveness as the biopharmaceutical sector enters a new phase marked by widespread patent expirations and favorable regulatory reforms. Between this year and 2034, nearly 50 brand-name drugs, each generating annual sales exceeding US$1 billion (NT$31 billion), are expected to lose patent protection. When a brand drug's patent expires, manufacturers are permitted to produce versions that are nearly identical to the original in therapeutic purpose, dosage form, safety, effectiveness, method of administration, and quality, according to the Taiwan Generic Pharmaceutical Association. More... |
| Rising CDMO demand: Tanvex BioPharma and EirGenix expand capacity to secure their positions 13 October, 2025 Amid the global biosimilar industry's structural transition and surging CDMO demand, Tanvex BioPharma (TW: 6541) and EirGenix (TW: 6589) are accelerating capacity expansion through dual-site strategies and integrated production chains to strengthen their international presence. Tanvex BioPharma's Zhubei site handles early development, while its San Diego plant focuses on commercial output, adding new 2,000-liter lines to boost capacity. EirGenix, advancing through reverse engineering, global certification, and alliances, has gained two market approvals for its breast cancer biosimilar EG12014 and expects US FDA clearance next year with Sandoz. Its CDMO business is also growing, supported by MHLW-certified API production in Xizhi. More... (in Chinese) |
| Bora Pharmaceuticals launches L1 ADR program, plans to list on US OTC Market Q1 next year 13 October, 2025 Taiwanese biotech leader Bora Pharmaceuticals (TW: 6472) reported September revenue of NT$1.72 billion, down 14.98% year-on-year, and announced that its board has approved plans to list its shares on the US over-the-counter market through overseas depositary receipts, launching a Level 1 ADR program. This makes Bora the first publicly listed Taiwanese company to pursue a Level 1 ADR, with US trading expected in Q1 next year. Bora Chairman Bobby Sheng said the Level 1 ADR issuance marks a key milestone in the company's globalization and entry into international capital markets, allowing overseas employees to hold shares via ADRs and strengthening their sense of belonging within the company. More... (in Chinese) |
| MetaTech partners with Japanese firm CM Plus to aid expansion into Asian markets 11 October, 2025 MetaTech (TW: 3224) and Japanese firm CM Plus signed a memorandum of understanding (MOU) on the 10th to combine AI technology with expertise in establishing a platform for generating and managing GMP (Good Manufacturing Practice) documentation for Taiwan-Japan biotech product launches, promoting the industry's digitalization and internationalization, and accelerating expansion into Asian markets. Their collaboration will focus on four key areas: GMP regulatory services, Southeast Asian market development, electronic document management, and Halal market expansion. MetaTech mentioned that the partnership will integrate MetaTech's strengths in AI, smart manufacturing, and data analytics into cell therapy and biotech product development processes to enhance production quality and documentation efficiency. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |